Xenetic Biosciences, Inc. (XBIO) earnings
XBIO earnings moved a median of +2.29% by the close. Quarterly and annual XBIO reports and results, each read against the price at its own news timestamp. Back to the XBIO overview →
25 measured XBIO earnings events.
Where these XBIO earnings landedvs 23 measured XBIO earnings reactions
| Middle 50% of XBIO earnings reactions | -1.77% to +7.87% |
|---|---|
| Median reaction (to close) | +2.29% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 XBIO earnings events with a measured close landed between -1.77% and +7.87%; 61% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform | Press release | +0.35% | +10.45% | |
| Form 10-Q Xenetic Biosciences, For: Jun 30 | SEC filing · Form 10-Q | +0.35% | +10.45% | |
| Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform | Press release | +5.93% | +7.80% | |
| Form 10-Q Xenetic Biosciences, For: Mar 31 | SEC filing · Form 10-Q | +5.93% | +7.80% | |
| Form 10-K/A Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -6.48% | |
| Form 10-K Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | -3.36% | -2.85% | |
| Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results | Press release | +0.00% | — | |
| Form 10-Q Xenetic Biosciences, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results | Press release | +4.69% | +7.94% | |
| Form 10-Q Xenetic Biosciences, For: Jun 30 | SEC filing · Form 10-Q | +4.69% | +7.94% | |
| Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | — | +2.29% | |
| Form 10-K/A Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | — | +2.29% | |
| Form 10-Q Xenetic Biosciences, For: Mar 31 | SEC filing · Form 10-Q | — | +2.29% | |
| Form 10-K/A Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | — | -0.35% | |
| Form 10-K Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +3.04% | |
| Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results | Press release | -2.24% | -8.98% | |
| Form 10-Q Xenetic Biosciences, For: Sep 30 | SEC filing · Form 10-Q | -2.24% | -8.98% | |
| Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +0.00% | +9.30% | |
| Form 10-Q Xenetic Biosciences, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +9.30% | |
| Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | — | -4.76% | |
| Form 10-Q Xenetic Biosciences, For: Mar 31 | SEC filing · Form 10-Q | — | -4.76% | |
| Form 10-K/A Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.76% | |
| Form 10-K Xenetic Biosciences, For: Dec 31 | SEC filing · Form 10-K | +2.74% | +5.75% | |
| Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results | Press release | +0.00% | -0.68% | |
| Form 10-Q Xenetic Biosciences, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -0.68% |
Keep exploring
More XBIO: analyst actions → · SEC filings → · XBIO overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| American Shared Hospital Services (AMS) | 121 | 0.00% | 48% |
| Protagenic Therapeutics, Inc. (PTIX) | 121 | 0.00% | 39% |
| Avenue Therapeutics, Inc. (ATXI) | 120 | 0.00% | 37% |
| CARL ZEISS MEDI UNSP/ADR (CZMWY) | 120 | -0.21% | 21% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.